Časopisi po područjima
Izvorni znanstveni članak
ML20474 STUDY: CROATIAN EXPERIENCE IN EFFICACY AND SAFETY OF ANEMIA CORRECTION IN PREDIALYSIS PATIENTS
; Merkur Clinical Hospital, Zagreb University School of Medicine, Department of Internal medicine, Zagreb, Croatia
; Zadar General Hospital, Department of Nephrology and Dialysis, Zadar, Croatia
; Bjelovar General Hospital, Department of Internal medicine, Bjelovar, Croatia
; Dubrava University Hospital, Department of Nephrology, Zagreb, Croatia
; Dubrovnik General Hospital, Department of Internal medicine, Dubrovnik, Croatia
; Rijeka University Hospital Center, Department of Nephrology and Dialysis, Rijeka, Croatia
Puni tekst: hrvatski, pdf (219 KB)
PRKAčIN, I., KLARIć, D., LOVčIć, V., GALEšIć, K., ILIć, M., RAčKI, S. (2016). STuDIJA ML20474 PRIMJENE ERITROPOETINA BETA (NEORECORMON) u LIJEčENJu ANEMIJE PREDIJALIZNIH BOLESNIKA – HRVATSKO ISKuSTVO. Acta medica Croatica, 70(Suplement 2), 18-18. Preuzeto s http://hrcak.srce.hr/180117
We performed observational multicenter study on CKD patients in stage 3-5, with renal anemia. Key inclusion criteria were: haemoglobin level > 6.0 g/dL, age >18 years and written inform consent. Exclusion criteria were dialysis and transplanted patients and haemoglobin level > 12.0 g/dL. Study was performed from 2006.-2012. and 368 patients were included. All patients received Erythropoietin beta (Neorecormon®; Roche, Basel, Switzerland) subcutaneously in dose of 4000-6000 IU every week during the correction phase of anemia treatment or once weekly 2000-4000IU during the maintenance treatment. Iron supplementation was administrated orally in >80% patients in order to achieve serum ferritin 200-500 μg/L. From 368 patients on beginning, 246 were followed and statistically analyzed (M:F=136/110). Mean duration study period was 13.6 (Std.dev.10.36) months (max 52 months). Patients were mainly men (55.3%), age >51 years (81.3%). The median of Hb level at baseline was 9.35 g/dL and after 12 months 10.4 g/dL respectively. After 12 months, most of patients had Hb range 10.0 g/dL to 11.0 g/dL. There were no statistically significant differences between Hb in groups of patients stratified according to the primary kidney disease and age, and between sex: mean level of Hb in M at the end of study was 10.27 g/dl and in F 10.58 g/dl (p=0.051). Baseline eGFR (Cocroft Gault) values were 16.31 (range form 4.1-62.6) vs. 16.71 (range from 4.9-43.8) mL/min after 12 months. The majority of patients had reported better exercise tolerance and sleep. 47.7% of patients have started after predialysis education with dialysis and in 2 patients preemptive transplantation was performed. The results of this multicenter observational study in Croatia suggest that the use of erythropoietin beta is effective and safe in correction of anemia in pre-dialysis CKD patients.
anemia; non-dialysis chronic kidney disease
Hrčak ID: 180117
Registracija novih korisnika
Zaboravili ste lozinku?